New Mexico Alzheimer's Disease Research Center
新墨西哥州阿尔茨海默病研究中心
基本信息
- 批准号:10450033
- 负责人:
- 金额:$ 101.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease diagnosisAlzheimer&aposs disease related dementiaAmerican IndiansAmyloidAreaAutopsyAwarenessBRAIN initiativeBasic ScienceBiologicalBiological MarkersBlood - brain barrier anatomyBlood VesselsCaringClinicClinicalClinical ServicesCognitionCognitiveCollaborationsCommunitiesCommunity HealthComplementDataData SetDatabasesDementiaDiffusion Magnetic Resonance ImagingDiseaseEducationEducational BackgroundEducational StatusElderlyFacultyFeedbackFunctional disorderFundingGeriatricsGoalsGrantImageImaging DeviceImpaired cognitionIncidenceInflammationInfrastructureInjuryLewy Body DementiaLiquid substanceLow incomeMRI ScansMagnetic Resonance ImagingMeasuresMedical centerMemoryMinorityMissionMovement DisordersNerve DegenerationNeuropsychological TestsNew MexicoNursing FacultyOutcomeParkinson&aposs DementiaParticipantPatient RecruitmentsPatientsPopulationPopulation HeterogeneityPopulation StudyPovertyPrevalencePreventionProcessPueblo RaceReduce health disparitiesResearchResearch PersonnelResourcesRewardsRiskRoleRuralRural CommunityRural PopulationSamplingScientistServicesSiteSocioeconomic StatusSpecialistStructureSystemTestingTrainingTravelTribal EldersTribesUniversitiesVascular DiseasesWorkZunibaseblood-brain barrier permeabilizationcognitive functioncognitive testingcomorbiditycontrast enhancedcost effectivedata repositorydementia careeducation researchgray matterhealth disparityhigh riskimprovedinterestmagnetic resonance imaging biomarkermedical schoolsmembermixed dementiamultimodalityneuropathologynon-geneticnoveloutreachpatient engagementpatient populationpatient stratificationprecision medicineprogramsranpirnaserecruitremote locationresponserural Americansscreeningsynergismtau Proteinstribal communityvascular cognitive impairment and dementiavascular factorvascular inflammationvascular risk factorwhite matter
项目摘要
ABSTRACT (Overall Core)
This proposal is to establish in New Mexico an exploratory Alzheimer's Disease Research Center (NM
eADRC). The Center goals are: 1) to build infrastructure and hire faculty to enhance Alzheimer's disease
(AD) research; 2) to meet the needs of rural communities with health disparities, and 3) to use
multimodal biomarkers, including CSF and MRI, to incorporate vascular disease into the new NIA-AA
Alzheimer's disease (AD) biological definition, improving patient stratefication. This P20 NM eADRC will
build toward the P30 ADRC. We plan to hire new faculty with expertise in Alzheimer's disease (AD) and
related dementias (RD). Infrastructure needs for care of the elderly will be met by the construction of new
7 million dollar building that will house three centers: Movement disorders, Geriatrics, and Center for
Memory and Aging, creating synergy in care of the elderly. The NM eADRC will address the unmet
needs in dementia care related to disparities, particularly in the large American Indian (AI) population.
There are challenges to improving dementia care to AI that include cultural insensitivity, low income and
educational levels, and long distances to travel for specialist care. We will overcome these barriers by
using community health representatives to perform cognitive screening and a program for mobile on-site
screening and testing (MOSST) that includes neuropsychological testing and mobile 1.5T MRI for
imaging. This will fill a gap in the national AD databases for data on minorities. Vascular disease is a
major co-morbidity with AD that accelerates the cognitive decline. It is estimated that up to 70% of
nongenetic AD is mixed dementia (MX), making this an important group to identify prior to autopsy. We
have developed biomarkers that can successfully stratify patients. This involves the use of CSF and MRI
studies, and allows for the addition of the vascular feature (V) to the amyloid (A), tau (T), and
neurodegeneration (N) components of the NIA-AA formula for diagnosis of AD. Biomarkers in the CSF
have been identified by the MarkVCID consortium that indicate inflammation, which occurs when both
AD and vascular disease are present. The NM eADRC will measure these unique biomarkers in the
newly recruited participants, and provide these services to other ADRCs that are interested. The blood-
brain barrier (BBB) has been implicated in the pathophysiology of AD. We plan to measure BBB
permeability in gray and white matter in patients with AD and RD along with VCID and MX to better
understand its role in dementia. The NM eADRC will be nidus for AD research to a large community of
researchers around the state and will be major center within the Medical School Administrative structure.
With the ability to bring in new faculty, build new buildings, and bring together the community of scientists
interested in dementia in NM, it will make a huge impact that will provide the infrastructure for a
successful P30 Center application.
摘要(整体核心)
该建议是在新墨西哥州建立探索性阿尔茨海默氏病研究中心(NM)
EADRC)。中心目标是:1)建立基础设施并聘请教师以增强阿尔茨海默氏病
(AD)研究; 2)满足健康差异的农村社区的需求,3)
包括CSF和MRI在内的多模式生物标志物将血管疾病纳入新的NIA-AA
阿尔茨海默氏病(AD)生物学定义,改善患者策略。这个P20 NM EADRC将
朝着P30 ADRC建立。我们计划聘请具有阿尔茨海默氏病(AD)和
相关痴呆症(RD)。新的基础设施需要照顾老年人的需求
700万美元的建筑将容纳三个中心:运动障碍,老年医学和中心
记忆和衰老,创造协同作用,以照顾老年人。 NM EADRC将解决未满足的
痴呆症护理的需求与差异有关,特别是在大型美洲印第安人(AI)人群中。
改善痴呆症护理对AI的挑战,包括文化不敏感,低收入和
教育水平和长途旅行以进行专业护理。我们将通过
使用社区卫生代表进行认知筛查和用于移动现场的计划
筛查和测试(MOSST),包括神经心理学测试和移动1.5T MRI
成像。这将填补国家广告数据库的空白,以获取有关少数群体的数据。血管疾病是
与AD的主要合并症可以加速认知能力下降。据估计,多达70%
Nongenetic AD是混合痴呆症(MX),使其成为尸检之前识别的重要组。我们
已经开发了可以成功分层患者的生物标志物。这涉及使用CSF和MRI
研究,并允许将血管特征(V)添加到淀粉样蛋白(a),tau(t)和
NIA-AA公式的神经变性(N)组件用于诊断AD。 CSF中的生物标志物
已经通过指示炎症的Markvcid联盟确定
存在AD和血管疾病。 NM EADRC将测量这些独特的生物标志物
新招募的参与者,并向有兴趣的其他ADRC提供这些服务。鲜血
脑屏障(BBB)与AD的病理生理有关。我们计划测量BBB
AD和RD患者以及VCID和MX的灰色和白质的渗透性,以更好
了解其在痴呆症中的作用。 NM EADRC将成为广告研究的NM
该州的研究人员将成为医学院行政结构的主要中心。
有能力带来新的教师,建造新建筑并将科学家社区融合在一起
对NM的痴呆症感兴趣,它将产生巨大的影响,将为A提供基础设施
成功的P30中心申请。
项目成果
期刊论文数量(17)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Reconfiguration of brain-wide neural activity after early life adversity.
早年逆境后全脑神经活动的重新配置。
- DOI:10.1101/2023.09.10.557058
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Uselman,TaylorW;Jacobs,RussellE;Bearer,ElaineL
- 通讯作者:Bearer,ElaineL
Microbiome-gut-brain dysfunction in prodromal and symptomatic Lewy body diseases.
前驱期和症状性路易体疾病中的微生物组-肠-脑功能障碍。
- DOI:10.1007/s00415-022-11461-9
- 发表时间:2023-03
- 期刊:
- 影响因子:6
- 作者:Ryman, Sephira;Vakhtin, Andrei A.;Richardson, Sarah Pirio;Lin, Henry C.
- 通讯作者:Lin, Henry C.
Microvascular Contributions to Alzheimer Disease Pathogenesis: Is Alzheimer Disease Primarily an Endotheliopathy?
- DOI:10.3390/biom13050830
- 发表时间:2023-05-13
- 期刊:
- 影响因子:5.5
- 作者:
- 通讯作者:
Selective In Vitro and Ex Vivo Staining of Brain Neurofibrillary Tangles and Amyloid Plaques by Novel Ethylene Ethynylene-Based Optical Sensors.
- DOI:10.3390/bios13020151
- 发表时间:2023-01-18
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Shared Inflammatory Pathology of Stroke and COVID-19.
- DOI:10.3390/ijms23095150
- 发表时间:2022-05-05
- 期刊:
- 影响因子:5.6
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gary Allen Rosenberg其他文献
Gary Allen Rosenberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gary Allen Rosenberg', 18)}}的其他基金
Validation of Biomarkers of Small Vessel Injury in VCID
VCID 中小血管损伤生物标志物的验证
- 批准号:
10611827 - 财政年份:2021
- 资助金额:
$ 101.9万 - 项目类别:
New Mexico Alzheimer's Disease Research Center
新墨西哥州阿尔茨海默病研究中心
- 批准号:
10038020 - 财政年份:2020
- 资助金额:
$ 101.9万 - 项目类别:
New Mexico Alzheimer's Disease Research Center
新墨西哥州阿尔茨海默病研究中心
- 批准号:
10227133 - 财政年份:2020
- 资助金额:
$ 101.9万 - 项目类别:
Validation of Biomarkers of Small Vessel Injury in VCID
VCID 中小血管损伤生物标志物的验证
- 批准号:
10369502 - 财政年份:2016
- 资助金额:
$ 101.9万 - 项目类别:
MRI and CSF Biomarkers of White Matter Injury in VCID
VCID 患者脑白质损伤的 MRI 和 CSF 生物标志物
- 批准号:
9356351 - 财政年份:2016
- 资助金额:
$ 101.9万 - 项目类别:
MRI and CSF Biomarkers of White Matter Injury in VCID
VCID 患者脑白质损伤的 MRI 和 CSF 生物标志物
- 批准号:
9768242 - 财政年份:2016
- 资助金额:
$ 101.9万 - 项目类别:
Matrix Metalloproteinase Inhibitors in Stroke
基质金属蛋白酶抑制剂在中风中的应用
- 批准号:
7845519 - 财政年份:2009
- 资助金额:
$ 101.9万 - 项目类别:
相似国自然基金
温度作用下CA砂浆非线性老化蠕变性能的多尺度研究
- 批准号:12302265
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于波动法的叠层橡胶隔震支座老化损伤原位检测及精确评估方法研究
- 批准号:52308322
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
微纳核壳结构填充体系构建及其对聚乳酸阻燃、抗老化、降解和循环的作用机制
- 批准号:52373051
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
东北黑土中农膜源微塑料冻融老化特征及其毒性效应
- 批准号:42377282
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
高层建筑外墙保温材料环境暴露自然老化后飞火点燃机理及模型研究
- 批准号:52376132
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Uncovering Mechanisms of Racial Inequalities in ADRD: Psychosocial Risk and Resilience Factors for White Matter Integrity
揭示 ADRD 中种族不平等的机制:心理社会风险和白质完整性的弹性因素
- 批准号:
10676358 - 财政年份:2024
- 资助金额:
$ 101.9万 - 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
- 批准号:
10749539 - 财政年份:2024
- 资助金额:
$ 101.9万 - 项目类别:
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimer's Disease
从肉体到细丝的流畅性:多尺度神经影像数据的整理、表示和分析,以表征和诊断阿尔茨海默病
- 批准号:
10462257 - 财政年份:2023
- 资助金额:
$ 101.9万 - 项目类别:
The contribution of air pollution to racial and ethnic disparities in Alzheimer’s disease and related dementias: An application of causal inference methods
空气污染对阿尔茨海默病和相关痴呆症的种族和民族差异的影响:因果推理方法的应用
- 批准号:
10642607 - 财政年份:2023
- 资助金额:
$ 101.9万 - 项目类别: